Investigating Osimertinib for Brain Activity in EGFR-Mutated Lung Cancer
Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of brain metastases in <em>EGFR</em>-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.
Suresh S. Ramalingam, MD, professor of hematology and medical oncology at the Emory University School of Medicine, discusses the challenge of treating brain metastases inEGFR-mutated lung cancer and the data surrounding osimertinib (Tagrisso) in this patient population.
In the FLAURA trial, presented at the 2019 European Lung Cancer Congress, osimertinib showed intracranial responses.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
